CA1217428A - Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same - Google Patents
Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using sameInfo
- Publication number
- CA1217428A CA1217428A CA000432884A CA432884A CA1217428A CA 1217428 A CA1217428 A CA 1217428A CA 000432884 A CA000432884 A CA 000432884A CA 432884 A CA432884 A CA 432884A CA 1217428 A CA1217428 A CA 1217428A
- Authority
- CA
- Canada
- Prior art keywords
- caffeine
- ibuprofen
- matter
- pharmaceutical composition
- analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 229960001680 ibuprofen Drugs 0.000 title claims abstract description 62
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title description 10
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 201
- 229960001948 caffeine Drugs 0.000 claims abstract description 99
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 98
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 98
- 230000031990 negative regulation of inflammatory response Effects 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- 230000003389 potentiating effect Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 23
- 208000002193 Pain Diseases 0.000 description 17
- 230000036407 pain Effects 0.000 description 17
- 239000003814 drug Substances 0.000 description 14
- 230000036592 analgesia Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 11
- 229960001138 acetylsalicylic acid Drugs 0.000 description 11
- 229960005489 paracetamol Drugs 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 229960003893 phenacetin Drugs 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000548 hind-foot Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PITMOJXAHYPVLG-UHFFFAOYSA-N 2-acetyloxybenzoic acid;n-(4-ethoxyphenyl)acetamide;1,3,7-trimethylpurine-2,6-dione Chemical compound CCOC1=CC=C(NC(C)=O)C=C1.CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C PITMOJXAHYPVLG-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 206010046823 Uterine spasm Diseases 0.000 description 1
- 229940086216 acetaminophen 150 mg Drugs 0.000 description 1
- 229940107186 acetaminophen 162.5 mg Drugs 0.000 description 1
- 229940032156 acetaminophen 260 mg Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940059275 anacin Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000002843 anti-caffeine Effects 0.000 description 1
- 229940078194 aspirin 210 mg Drugs 0.000 description 1
- 229940098003 aspirin 325 mg Drugs 0.000 description 1
- 229940032153 aspirin 520 mg Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229940085881 caffeine 32.5 mg Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- -1 citris pulp Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940085392 excedrin Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 229940072709 motrin Drugs 0.000 description 1
- 208000017445 musculoskeletal system disease Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- JWBPVFVNISJVEM-UHFFFAOYSA-M sodium caffeine benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C JWBPVFVNISJVEM-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000002693 spinal anesthesia Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/400,645 US4420483A (en) | 1982-07-22 | 1982-07-22 | Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same |
| US400,645 | 1982-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1217428A true CA1217428A (en) | 1987-02-03 |
Family
ID=23584445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000432884A Expired CA1217428A (en) | 1982-07-22 | 1983-07-21 | Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4420483A (en, 2012) |
| JP (1) | JPS59501413A (en, 2012) |
| AT (1) | AT389051B (en, 2012) |
| AU (1) | AU560092B2 (en, 2012) |
| BE (1) | BE897355A (en, 2012) |
| CA (1) | CA1217428A (en, 2012) |
| CH (1) | CH659946A5 (en, 2012) |
| DE (1) | DE3390114T1 (en, 2012) |
| FR (1) | FR2530468B1 (en, 2012) |
| GB (1) | GB2132891B (en, 2012) |
| IE (1) | IE55366B1 (en, 2012) |
| IT (1) | IT1206693B (en, 2012) |
| NL (1) | NL190923C (en, 2012) |
| SE (1) | SE466889B (en, 2012) |
| WO (1) | WO1984000487A1 (en, 2012) |
| ZA (1) | ZA835325B (en, 2012) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3348444C2 (de) * | 1982-07-22 | 1995-02-02 | Richardson Vicks Inc | Analgetische und antiinflammatorische Mittel |
| US4559343A (en) * | 1982-09-07 | 1985-12-17 | Alcon Laboratories, Inc. | Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents |
| US4558051A (en) * | 1983-10-11 | 1985-12-10 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
| US4522826A (en) * | 1984-02-08 | 1985-06-11 | Richardson-Vicks Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
| AU5132893A (en) * | 1992-09-29 | 1994-04-26 | Mcneil-Ppc, Inc. | Ibuprofen-caffeine combinations |
| AU672279B2 (en) * | 1992-12-21 | 1996-09-26 | Procter & Gamble Company, The | Compositions containing caffeine and S(+)-ibuprofen or S(+)-flurbiprofen or S(+)-ketoprofen |
| AU676315B2 (en) * | 1993-06-30 | 1997-03-06 | Takeda Chemical Industries Ltd. | Stabilized solid pharmaceutical preparation and method of producing the same |
| JPH09502202A (ja) * | 1993-09-07 | 1997-03-04 | ザ、プロクター、エンド、ギャンブル、カンパニー | プロピオン酸非ステロイド系抗炎症剤のアミノ酸塩とカフェインを含有した組成物 |
| JPH0987174A (ja) * | 1995-09-26 | 1997-03-31 | Kobayashi Pharmaceut Co Ltd | 鎮痛性および抗炎症性組成物 |
| US6348216B1 (en) * | 1996-06-10 | 2002-02-19 | Knoll Pharmaceutical Company | Ibuprofen and narcotic analgesic compositions |
| US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
| US20020177626A1 (en) * | 2001-01-19 | 2002-11-28 | Cook Graham D. | Treatment of sleep disturbances |
| USD472507S1 (en) | 2001-06-06 | 2003-04-01 | Campagnolo Srl | Spoked wheel for bicycles |
| JP2003277258A (ja) * | 2002-03-20 | 2003-10-02 | Ss Pharmaceut Co Ltd | 片頭痛治療剤 |
| US7332525B2 (en) * | 2003-01-17 | 2008-02-19 | Castle Erik P | Method of treatment of prostate cancer and composition for treatment thereof |
| US20050065172A1 (en) * | 2003-09-23 | 2005-03-24 | Shah Indukumar G. | Solid dosage form comprising caffeine |
| WO2009073946A1 (en) * | 2007-12-12 | 2009-06-18 | Multi Formulations Ltd. | Particles in a capsule |
| ES2932980T3 (es) * | 2014-08-28 | 2023-01-30 | Sanofi Aventis Deutschland | Comprimido recubierto con película para el tratamiento del dolor agudo |
| CA2958454A1 (en) * | 2014-08-28 | 2016-03-03 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for the treatment of acute tooth or jaw pain |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5423132A (en) * | 1977-07-19 | 1979-02-21 | Dai Ichi Seiyaku Co Ltd | Analgesic composition |
| JPS5697224A (en) * | 1979-12-28 | 1981-08-05 | Kaken Pharmaceut Co Ltd | Antipyretic analgesic composition |
| JPS56154416A (en) * | 1980-04-30 | 1981-11-30 | Kaken Pharmaceut Co Ltd | Antipyretic analgesic composition |
-
1982
- 1982-07-22 US US06/400,645 patent/US4420483A/en not_active Expired - Lifetime
-
1983
- 1983-07-21 GB GB08406703A patent/GB2132891B/en not_active Expired
- 1983-07-21 IE IE1714/83A patent/IE55366B1/en not_active IP Right Cessation
- 1983-07-21 WO PCT/US1983/001120 patent/WO1984000487A1/en active Application Filing
- 1983-07-21 ZA ZA835325A patent/ZA835325B/xx unknown
- 1983-07-21 AT AT0903883A patent/AT389051B/de not_active IP Right Cessation
- 1983-07-21 DE DE19833390114 patent/DE3390114T1/de active Granted
- 1983-07-21 NL NL8320239A patent/NL190923C/xx not_active IP Right Cessation
- 1983-07-21 IT IT8322172A patent/IT1206693B/it active
- 1983-07-21 CA CA000432884A patent/CA1217428A/en not_active Expired
- 1983-07-21 JP JP58502639A patent/JPS59501413A/ja active Granted
- 1983-07-21 AU AU18287/83A patent/AU560092B2/en not_active Expired
- 1983-07-21 CH CH1545/84A patent/CH659946A5/de not_active IP Right Cessation
- 1983-07-21 FR FR8312111A patent/FR2530468B1/fr not_active Expired
- 1983-07-22 BE BE0/211219A patent/BE897355A/fr unknown
-
1984
- 1984-03-20 SE SE8401537A patent/SE466889B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE3390114T1 (de) | 1985-01-10 |
| DE3390114C2 (en, 2012) | 1990-07-05 |
| IT1206693B (it) | 1989-04-27 |
| JPS59501413A (ja) | 1984-08-09 |
| US4420483A (en) | 1983-12-13 |
| IE55366B1 (en) | 1990-08-29 |
| IT8322172A0 (it) | 1983-07-21 |
| GB8406703D0 (en) | 1984-04-18 |
| GB2132891A (en) | 1984-07-18 |
| AT389051B (de) | 1989-10-10 |
| SE466889B (sv) | 1992-04-27 |
| GB2132891B (en) | 1986-05-08 |
| NL190923C (nl) | 1994-11-01 |
| IE831714L (en) | 1984-01-22 |
| AU560092B2 (en) | 1987-03-26 |
| FR2530468B1 (fr) | 1987-01-16 |
| SE8401537L (sv) | 1984-03-20 |
| WO1984000487A1 (en) | 1984-02-16 |
| BE897355A (fr) | 1983-11-14 |
| AU1828783A (en) | 1984-02-23 |
| JPH0124131B2 (en, 2012) | 1989-05-10 |
| ZA835325B (en) | 1984-09-26 |
| NL8320239A (nl) | 1984-06-01 |
| NL190923B (nl) | 1994-06-01 |
| SE8401537D0 (sv) | 1984-03-20 |
| FR2530468A1 (fr) | 1984-01-27 |
| CH659946A5 (de) | 1987-03-13 |
| ATA903883A (de) | 1989-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1217428A (en) | Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same | |
| US4486436A (en) | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | |
| Malamed et al. | Articaine hydrochloride: a study of the safety of a new amide local anesthetic | |
| US4567183A (en) | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same | |
| IE58158B1 (en) | Analgesic and anti-inflammatory compositions comprising xanthines | |
| US4464376A (en) | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | |
| US4656177A (en) | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | |
| US4777174A (en) | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | |
| CA1217429A (en) | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | |
| US4587249A (en) | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | |
| US4479956A (en) | Analgesic compositions comprising propiram and methods of using same | |
| WO1995007690A1 (en) | Composition and method for treating nicotine craving in smoking cessation | |
| JPH0141608B2 (en, 2012) | ||
| Cooper et al. | Analgesic relative potency assay comparing flurbiprofen 50, 100, and 150 mg, aspirin 600 mg, and placebo in postsurgical dental pain | |
| EP0013110A1 (en) | Analgesic composition | |
| DE3348444C2 (de) | Analgetische und antiinflammatorische Mittel | |
| WO1993018768A1 (en) | Combinations of parasympathomimetic agents with muscarinic antagonists for treating nicotine craving in smoking cessation | |
| JPH0959149A (ja) | 消炎鎮痛組成物 | |
| EDWARD | TREATMENT OF RHEUMATIC FEVER WITH A MAGNESIUM CINCHOPHEN, MAGNESIUM OXIDE (MAGNEPHEN) PREPARATION” | |
| JP2005289904A (ja) | 医薬組成物 | |
| Odeh | Falciparum malaria and hypoglycaemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |